Sustainable and environmental catalysis

Assente in quanto editorial

PRIN LEVANTE 2020: Levulinic acid valorization through advanced novel technologies

The project LEVANTE deals with the development of new catalytic processes for the valorization of levulinic acid and its esters towards three classes of compounds: levulinic ketals, diphenolic acid and γ-valerolactone together with other reduction products

Uncovering relationships between Management Innovation and Service Innovation, time lags and performance

Conference Theme: Shaping the future: transforming public management - 'Re-invention or 'revolution'?The study focuses on public service innovation because it is a critically important area of investigation that scholars, policy makers and public administrators maintain delivers economic, political and social benefits (Borins, 1998; Tidd, Bessant and Pavitt 2009). Public organizations have put in place a range of innovative practices that bring societal benefits, but more needs to be known about public service innovation, and in particular its performance consequences (Damanpour, Walker and Avellaneda 2009; Walker and Damanpour 2008). Innovations come in different guises. In this study we focus on ...postprin

Glycerol Carbonate as a Versatile Alkylating Agent for the Synthesis of β-Aryloxy Alcohols

The possibility to use glycerol carbonate (GlyC) as an innovative alkylating agent for phenolic compounds in solventless conditions and in the presence of a catalytic amount of both homogeneous and heterogeneous bases is herein described. In particular, the peculiar, polyfunctional structure of GlyC allows one to obtain the formation not only of the mono-phenoxy-1,2-propanediol (MPP) analogue but also of 1,3-diphenoxy-2-propanol (DPP), the latter being elusive using the more traditional, toxic, and carcinogenic reagents such as glycidol and/or 3-chloro-1,2-propandiol. The production of DPP is indeed possible due to the in situ formation of a reactive intermediate, 4-(phenoxy)methyl-1,3-dioxolane-2-one (PhOGlyC), which may undergo a consecutive nucleophilic attack of a phenolate, leading to the selective formation of the disubstituted product. This reaction is nonetheless in competition with PhOGlyC decarboxylation that finally limits DPP yield up to 20%, with an MPP yield up to roughly 60% in the optimized conditions (atmospheric pressure, 140 degrees C, 5 h using Cs2CO3 as the basic catalyst) starting directly from a GlyC/phenolic mixture. For this reason, a multistep synthetic strategy has also been developed, first by obtaining the quantitative formation and isolation of the PhOGlyC intermediate and then by promoting the consecutive reaction with phenol, in this way obtaining a DPP yield of 66% after only 1 h of reaction at 170 degrees C. The obtained phenyl glyceryl ethers are interesting drugs scaffolds (i.e., guaifenesin, mephenesin), intermediates in the preparation of active pharmaceutical ingredients (e.g., chlorphenesin carbamate, methocarbamol), and hydrotropic solvents; preliminary evaluations of MPP and DPP biodegradability and use as alternative surfactants have also been described in this paper

Nutritional Management of Oncological Symptoms: A Comprehensive Review

Throughout their experience of illness and during the course of treatment, a substantial proportion of cancer patients are prone to develop nutritional and/or metabolic disturbances. Additionally, cancer patients often encounter long-term side effects from therapies, which may lead to impaired digestion, nutrient absorption or bowel motility. Therefore, the preservation and maintenance of an optimal and balanced nutritional status are pivotal to achieving a better prognosis, increasing the tolerance and adherence to cancer therapies and improving the overall quality of life. In this context, personalized nutritional programs are essential for addressing conditions predisposing to weight loss, feeding difficulties, digestion problems and intestinal irregularity, with the goal of promoting adequate nutrient absorption and minimizing the detrimental effects of treatment regimens. The focus of this research is to examine the most common clinical conditions and metabolic changes that cancer patients may experience, including stomatitis, xerostomia, diarrhea, nausea, vomiting, dysphagia, sub-occlusion, dysgeusia, dysosmia, anorexia, and cachexia. Furthermore, we present a pragmatic example of a multidisciplinary workflow that incorporates customized recipes tailored to individual clinical scenarios, all while maintaining the hedonic value of the meals

The relationship between emotional regulation and eating behaviour: a multidimensional analysis of obesity psychopathology

The aim of this study is to show that the differences among eating behaviours are related to the emotional dysregulation connected to the mental dimensions being part of the obese psychopathology. Eating behaviours can be considered a diagnostic feature at the initial screening for determining the obesity treatment: nutritional or bariatric surgery

ChiMiCapisce

This year, for the first time, the Young Chemists Group of the Italian Chemical Society (SCI) organized a national communication contest dedicated to chemists under 35. The contest, called ChiMiCapisce—a play on "Chimica", Italian for chemistry, and "Chi Mi Capisce?", which literally means "Who can understand me?"—was planned as the launch event of the recently established “Dissemination of Chemical Culture” Division of the Italian Chemical Society

Proceedings of the Merck & Elsevier Young Chemists Symposium (MEYCS 2018)

Dear participants, welcome to the 18th edition of the Merck & Elsevier Young Chemists Symposium, formerly SAYCS and MYCS. This conference is an international scientific event organized by the Young Group of the Italian Chemical Society (SCI Giovani) with the financial support of Merck and Elsevier. This symposium is fully devoted to young researchers, such as MSc and PhD students, post-doc fellows and young researchers in companies. All the disciplines of Chemistry are covered: analytical, physical, industrial, organic, inorganic, theoretical, pharmaceutical, biological, environmental, macromolecular and electrochemistry. This year, a special emphasis will be given to chemistry from knowledge to innovation: how chemistry is increasingly present in all of the fields that are essential for human life, and how chemical fundamentals are pushing novel technologies? This year we have the exceptional number of 212 participants; we thank you for the great trust shown towards SCI Giovani, Merck and Elsevier. Enjoy the conference

Intravitreal Brolucizumab for Pachychoroid Neovasculopathy Associated With Chronic Central Serous Chorioretinopathy

Purpose: To evaluate the anatomical and functional outcomes of intravitreal brolucizumab in eyes with chronic central serous chorioretinopathy complicated by pachychoroid neovasculopathy. Methods: Retrospective analysis of 34 eyes treated with intravitreal brolucizumab. Twenty-five eyes (73.5%) had been treated with other anti-vascular endothelial growth factor agents before switching to brolucizumab, whereas nine eyes were naïve. Outcome measures included the change of central foveal thickness and subfoveal choroidal thickness, evaluation of sub/intraretinal fluid on optical coherence tomography, and change in best-corrected visual acuity. Results: Before starting brolucizumab, 23 eyes showed subretinal fluid, 8 both subretinal and intraretinal fluid, and 3 intraretinal fluid only. At the last visit, 22 eyes (64.7%) showed complete reabsorption of both intraretinal and subretinal fluid, whereas subretinal fluid was still present in 8 eyes (23.5%), and both intraretinal and subretinal fluid in 4 eyes (11.8%). The mean number of brolucizumab injections required to achieve complete fluid reabsorption was 2.8 ± 1.8. central foveal thickness decreased from 317.8 ± 109.3 μm to 239.8 ± 74.8 μm (P = 0.0005) and subfoveal choroidal thickness decreased from 399.3 ± 86.2 μm to 355.5 ± 92.7 μm at the end of the follow-up period (P = 0.0008). The mean logarithm of the minimum angle of resolution best-corrected visual acuity improved from 0.4 ± 0.2 to 0.3 ± 0.2 at 1 month after the first injection and remained stable at the same values at the end of the follow-up period (P = 0.04). Conclusions: Intravitreal brolucizumab is effective for the treatment of naïve and recalcitrant pachychoroid neovasculopathy. Translational relevance: Intravitreal brolucizumab may represent an option in patients with pachychoroid neovasculopathy complicating chronic central serous chorioretinopathy